Pfizer Faces Challenges but Remains a Worthy Investment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Vaccine Demand Decline: Pfizer's stock has plunged over 50% from its 2021 peak due to cooling demand for COVID vaccines, yet it remains a potential investment for those with a long-term perspective despite short-term challenges.
- Patent Cliff Risks: The company is facing a series of upcoming patent expirations that could lead to significant revenue declines for key drugs, presenting a major challenge for management to maintain revenue stability.
- Innovative Drug Development: Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm to distribute a GLP-1 drug if approved, demonstrating its proactive approach in the innovative pharmaceutical space.
- High Dividend Appeal: With a dividend yield of 6.4%, Pfizer offers a more attractive option for dividend investors compared to Eli Lilly's mere 0.6%, making it appealing in a market characterized by uncertainty.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.700
Low
24.00
Averages
28.56
High
35.00
Current: 26.700
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Inc. Rated as Low-Risk Investment
- Rating and Price Target: Guggenheim reaffirmed a Buy rating for Pfizer on April 13, setting a price target of $36, reflecting confidence in the company's future performance ahead of its Q1 earnings report.
- Financial Forecast Adjustment: The firm anticipates Q1 revenues of approximately $13.8 billion, slightly below the $13.9 billion consensus, while expecting earnings per share of $0.76, surpassing the $0.72 forecast, indicating improved profitability.
- Full-Year Outlook: For 2026, Pfizer's projected revenue and EPS are $61.3 billion and $3, respectively, exceeding the consensus of $61.2 billion and $2.96, showcasing strong growth potential despite upcoming patent expirations.
- Investor Focus: Guggenheim suggests that investor attention will be on upcoming pipeline readouts, which could drive Pfizer's expansion during the critical 2026-2028 period of major patent expirations, enhancing market confidence.
See More
Pfizer Faces Challenges but Remains a Worthy Investment
- Vaccine Demand Decline: Pfizer's stock has plunged over 50% from its 2021 peak due to cooling demand for COVID vaccines, yet it remains a potential investment for those with a long-term perspective despite short-term challenges.
- Patent Cliff Risks: The company is facing a series of upcoming patent expirations that could lead to significant revenue declines for key drugs, presenting a major challenge for management to maintain revenue stability.
- Innovative Drug Development: Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm to distribute a GLP-1 drug if approved, demonstrating its proactive approach in the innovative pharmaceutical space.
- High Dividend Appeal: With a dividend yield of 6.4%, Pfizer offers a more attractive option for dividend investors compared to Eli Lilly's mere 0.6%, making it appealing in a market characterized by uncertainty.
See More
Pfizer Stock Still Holds Investment Value
- Declining Vaccine Demand: Pfizer's stock has plunged over 50% from its 2021 peak due to cooling demand for COVID vaccines, compounded by upcoming patent cliffs that could significantly impact revenue, affecting the company's short-term financial performance.
- New Drug Development: Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm on a GLP-1 drug, which, if approved, could enhance its market competitiveness and boost future revenue potential.
- Dividend Appeal: Despite facing uncertainties, Pfizer's 6.4% dividend yield is significantly higher than Eli Lilly's 0.6%, providing investors with stable cash flow and attracting long-term investors' interest.
- Market Position and Outlook: Pfizer continues to advance its drug development efforts in oncology and migraine treatments, and history suggests the company can regain growth; if successful in launching new drugs, it could enhance its market valuation and transition into a growth stock.
See More
Pfizer Faces Headwinds but Remains Promising
- Declining Vaccine Demand: Pfizer is facing challenges due to a drop in demand for COVID vaccines, resulting in its stock price plummeting over 50% from its 2021 peak, which has led investors to adopt a cautious outlook on its future performance.
- Patent Cliff Risks: The company is approaching a series of patent expirations that are expected to lead to significant revenue declines for some of its key drugs, posing a threat to its financial health and market position.
- New Drug Development Progress: Despite these challenges, Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm to distribute a GLP-1 drug, demonstrating its ongoing commitment to innovation in the pharmaceutical sector.
- Dividend Appeal: With a dividend yield of 6.4%, Pfizer remains an attractive option for income-seeking investors, especially when compared to competitors like Eli Lilly, which offers a mere 0.6% yield, despite the near-term uncertainties surrounding its drug pipeline.
See More
Major Companies Reporting Earnings Next Week
- Strong Earnings Season Start: So far, 63% of S&P 500 members have reported earnings, with 84% exceeding analyst expectations, indicating market resilience and improved corporate profitability, which could positively impact stock prices.
- Palantir Earnings Expectations: Palantir Technologies is set to report earnings after the market closes on Monday, with analysts expecting earnings to more than double year-over-year due to strong AI and defense demand, potentially driving its stock price higher.
- Pfizer Drug Approval: Pfizer is scheduled to report earnings on Tuesday, and although a double-digit decline in earnings is expected, the FDA's approval of the breast cancer drug Veppanu may provide new revenue growth opportunities, with analysts remaining optimistic.
- McDonald's Earnings Outlook: McDonald's will report earnings on Thursday, with analysts forecasting single-digit growth in earnings and revenue, and the recovery in U.S. traffic suggests business revival potential, despite ongoing cost pressures.
See More
FDA Approves Pfizer and Arvinas Breast Cancer Drug
- New Drug Approval: The FDA has approved Veppanu, a breast cancer drug developed by Pfizer and Arvinas, specifically designed for advanced patients with a specific genetic mutation, marking a significant advancement in treatment options.
- Clinical Trial Results: In a late-stage trial involving 624 participants, Veppanu demonstrated a significant extension in the duration of patients' survival without disease progression compared to the traditional hormone therapy fulvestrant, indicating competitive efficacy.
- Market Outlook: Arvinas CEO Randy Teel stated that Veppanu provides a much-needed treatment option for stage-4 breast cancer patients, with plans to announce a commercialization deal in the coming weeks to clarify pricing strategies.
- Companion Test Approval: The FDA also approved the Guardant360 CDx blood test to identify patients carrying the ESR1 mutation, ensuring the drug's targeted application and enhancing treatment effectiveness.
See More
Pfizer Inc. Rated as Low-Risk Investment
- Rating and Price Target: Guggenheim reaffirmed a Buy rating for Pfizer on April 13, setting a price target of $36, reflecting confidence in the company's future performance ahead of its Q1 earnings report.
- Financial Forecast Adjustment: The firm anticipates Q1 revenues of approximately $13.8 billion, slightly below the $13.9 billion consensus, while expecting earnings per share of $0.76, surpassing the $0.72 forecast, indicating improved profitability.
- Full-Year Outlook: For 2026, Pfizer's projected revenue and EPS are $61.3 billion and $3, respectively, exceeding the consensus of $61.2 billion and $2.96, showcasing strong growth potential despite upcoming patent expirations.
- Investor Focus: Guggenheim suggests that investor attention will be on upcoming pipeline readouts, which could drive Pfizer's expansion during the critical 2026-2028 period of major patent expirations, enhancing market confidence.
See More
Pfizer Faces Challenges but Remains a Worthy Investment
- Vaccine Demand Decline: Pfizer's stock has plunged over 50% from its 2021 peak due to cooling demand for COVID vaccines, yet it remains a potential investment for those with a long-term perspective despite short-term challenges.
- Patent Cliff Risks: The company is facing a series of upcoming patent expirations that could lead to significant revenue declines for key drugs, presenting a major challenge for management to maintain revenue stability.
- Innovative Drug Development: Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm to distribute a GLP-1 drug if approved, demonstrating its proactive approach in the innovative pharmaceutical space.
- High Dividend Appeal: With a dividend yield of 6.4%, Pfizer offers a more attractive option for dividend investors compared to Eli Lilly's mere 0.6%, making it appealing in a market characterized by uncertainty.
See More
Pfizer Stock Still Holds Investment Value
- Declining Vaccine Demand: Pfizer's stock has plunged over 50% from its 2021 peak due to cooling demand for COVID vaccines, compounded by upcoming patent cliffs that could significantly impact revenue, affecting the company's short-term financial performance.
- New Drug Development: Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm on a GLP-1 drug, which, if approved, could enhance its market competitiveness and boost future revenue potential.
- Dividend Appeal: Despite facing uncertainties, Pfizer's 6.4% dividend yield is significantly higher than Eli Lilly's 0.6%, providing investors with stable cash flow and attracting long-term investors' interest.
- Market Position and Outlook: Pfizer continues to advance its drug development efforts in oncology and migraine treatments, and history suggests the company can regain growth; if successful in launching new drugs, it could enhance its market valuation and transition into a growth stock.
See More
Pfizer Faces Headwinds but Remains Promising
- Declining Vaccine Demand: Pfizer is facing challenges due to a drop in demand for COVID vaccines, resulting in its stock price plummeting over 50% from its 2021 peak, which has led investors to adopt a cautious outlook on its future performance.
- Patent Cliff Risks: The company is approaching a series of patent expirations that are expected to lead to significant revenue declines for some of its key drugs, posing a threat to its financial health and market position.
- New Drug Development Progress: Despite these challenges, Pfizer has quickly pivoted by acquiring a company developing a weight-loss drug and partnering with a Chinese firm to distribute a GLP-1 drug, demonstrating its ongoing commitment to innovation in the pharmaceutical sector.
- Dividend Appeal: With a dividend yield of 6.4%, Pfizer remains an attractive option for income-seeking investors, especially when compared to competitors like Eli Lilly, which offers a mere 0.6% yield, despite the near-term uncertainties surrounding its drug pipeline.
See More
Major Companies Reporting Earnings Next Week
- Strong Earnings Season Start: So far, 63% of S&P 500 members have reported earnings, with 84% exceeding analyst expectations, indicating market resilience and improved corporate profitability, which could positively impact stock prices.
- Palantir Earnings Expectations: Palantir Technologies is set to report earnings after the market closes on Monday, with analysts expecting earnings to more than double year-over-year due to strong AI and defense demand, potentially driving its stock price higher.
- Pfizer Drug Approval: Pfizer is scheduled to report earnings on Tuesday, and although a double-digit decline in earnings is expected, the FDA's approval of the breast cancer drug Veppanu may provide new revenue growth opportunities, with analysts remaining optimistic.
- McDonald's Earnings Outlook: McDonald's will report earnings on Thursday, with analysts forecasting single-digit growth in earnings and revenue, and the recovery in U.S. traffic suggests business revival potential, despite ongoing cost pressures.
See More
FDA Approves Pfizer and Arvinas Breast Cancer Drug
- New Drug Approval: The FDA has approved Veppanu, a breast cancer drug developed by Pfizer and Arvinas, specifically designed for advanced patients with a specific genetic mutation, marking a significant advancement in treatment options.
- Clinical Trial Results: In a late-stage trial involving 624 participants, Veppanu demonstrated a significant extension in the duration of patients' survival without disease progression compared to the traditional hormone therapy fulvestrant, indicating competitive efficacy.
- Market Outlook: Arvinas CEO Randy Teel stated that Veppanu provides a much-needed treatment option for stage-4 breast cancer patients, with plans to announce a commercialization deal in the coming weeks to clarify pricing strategies.
- Companion Test Approval: The FDA also approved the Guardant360 CDx blood test to identify patients carrying the ESR1 mutation, ensuring the drug's targeted application and enhancing treatment effectiveness.
See More
